Research programme: HIV viral entry inhibitors - Sienna Biopharmaceuticals

Drug Profile

Research programme: HIV viral entry inhibitors - Sienna Biopharmaceuticals

Alternative Names: CT 319; CT 326; HIV viral entry inhibitors research programme - Sienna Biopharmaceuticals

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Creabilis Therapeutics; University of Turin
  • Class
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 06 Dec 2016 Creabilis Therapeutics has been acquired by Sienna Biopharmaceuticals
  • 01 Sep 2005 Preclinical trials in HIV infections prevention in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top